Quoin Pharmaceuticals (QNRX) Non Operating Income (2021 - 2026)
Quoin Pharmaceuticals (QNRX) posted Non Operating Income of $133475.0 for Q1 2026, down 22.43% sequentially from $172062.0 in Q4 2025, and down 7.95% YoY from $144998.0 in Q1 2025.
Quoin Pharmaceuticals (QNRX) Non Operating Income (2021 - 2026) Analysis & Trends
Quoin Pharmaceuticals has reported Non Operating Income for 6 years, with the latest figure at $133475.0 in Q1 2026.
- Quarterly Non Operating Income fell 7.95% year-over-year to $133475.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $474538.0 (down 18.18% YoY) and the FY2025 annual result came in at $486061.0, down 14.12% from the prior year.
- Non Operating Income declined to $133475.0 in Q1 2026 per QNRX's latest filing, from $172062.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $493237.0 in Q1 2022 and troughed at -$702002.0 in Q3 2022.
- A 5-year average of $107700.3 and a median of $144998.0 in 2025 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income plunged 592.6% in 2022, then jumped 128.28% in 2023.
- Over 5 years, Non Operating Income stood at $84973.0 in 2022, then soared by 97.46% to $167789.0 in 2023, then sank by 44.1% to $93787.0 in 2024, then jumped by 83.46% to $172062.0 in 2025, then declined by 22.43% to $133475.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $133475.0, $172062.0, and $71760.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Quoin Pharmaceuticals | 531,643.73 | 531,643.73 | - | 102,532.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 133,475.00 |
| Dec 31, 2025 | 172,062.00 |
| Sep 30, 2025 | 71,760.00 |
| Jun 30, 2025 | 97,241.00 |
| Mar 31, 2025 | 144,998.00 |
| Dec 31, 2024 | 93,787.00 |
| Sep 30, 2024 | 178,117.00 |
| Jun 30, 2024 | 163,085.00 |
| Mar 31, 2024 | 131,004.00 |
| Dec 31, 2023 | 167,789.00 |
| Sep 30, 2023 | 198,544.00 |
| Jun 30, 2023 | 153,117.00 |
| Mar 31, 2023 | 172,481.00 |
| Dec 31, 2022 | 84,973.00 |
| Sep 30, 2022 | -702,002.00 |
| Jun 30, 2022 | 77,237.00 |
| Mar 31, 2022 | 493,237.00 |
| Dec 31, 2021 | -8.84 Mn |
| Sep 30, 2021 | -101,357.00 |
| Jun 30, 2021 | -3.36 Mn |